Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Noninvasive Screening for Fetal Aneuploidy: A New Maternal Plasma Marker

NCT00971334 is registered in ClinicalTrials.gov with Sequenom, Inc. as lead sponsor.

NCT NCT00971334
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00971334 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Noninvasive Screening for Fetal Aneuploidy: A New Maternal Plasma Marker
Lead sponsor
Sequenom, Inc.
Phase
Observational
Overall status
Completed
Start date
August 31, 2009
Completion date
December 31, 2011
Enrollment
2,502 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

aneuploidy, down syndrome, edwards syndrome, pregnancy